Summary
Purpose Imexon is an iminopyrrolidone that induces apoptosis and has synergistic activity with docetaxel in preclinical models. This trial was designed to establish the maximum tolerated dose (MTD) of imexon given with docetaxel in breast, prostate and non-small cell lung cancer (NSCLC). Patients and Methods 34 patients received protocol therapy. 26 patients received escalating doses of imexon given intravenously over 60 min on days 1–5 every 21 days. Docetaxel was administered intravenously at a fixed dose of 75 mg/m2 immediately following imexon on day 1 every 21 days. A 3+3 design was used with eight additional patients treated at MTD. Response was measured using RECIST. Results Seven dose levels of imexon were evaluated (390 mg/m2 to 1,700 mg/m2). The MTD was imexon 1,300 mg/m2 IV on days 1–5 in combination with docetaxel. Dose limiting toxicities were grade 3 non-cardiac chest pain and grade 3 diarrhea. Activity was seen in 4 patients [2 partial responses (NSCLC (PR=1), prostate cancer (PR=1)), 2 minor responses (MR=breast, NSCLC)]. Eleven patients had stable disease by RECIST (including the patients with MR; prostate cancer=6, NSCLC=3). Six (one with breast cancer, two with prostate cancer and three with NSCLC) demonstrated stable disease (SD) for ≥ 3 months. Conclusion The MTD of combination therapy is imexon 1,300 mg/m2 IV on days 1–5 with docetaxel 75 mg/m2 IV on day 1 of a 21 day treatment cycle. Demonstrated responses warrant further investigation in phase II trials of which a phase II trial in NSCLC is planned.
Similar content being viewed by others
References
Iyengar BS, Dorr RT, Remers WA (2004) Chemical basis for the biological activity of imexon and related cyanoaziridines. J of Med Chem 47:218–23
Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT (2000) Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 60:749–58
Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT (2001) Induction of mitochondrial changes in myeloma cells by imexon. Blood 97:3544–51
Dragovich T, Gordon M, Mendelson D et al (2007) Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 25:1779–84
Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT (2002) Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anti-cancer drugs 13:1031–42
Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE (1992) Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst 84:1238–44
Pourpak A, Meyers RO, Samulitis BK et al (2006) Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anti-cancer drugs 17:1179–84
Scott J, Dorr RT, Samulitis B, Landowski TH (2007) Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol 59:749–57
Park JS, Yamamoto W, Sekikawa T et al (2002) Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol 20:333–8
Iwao-Koizumi K, Matoba R, Ueno N et al (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23:422–31
Dorr RT, Liddil JD, Klein MK, Hersh EM (1995) Preclinical pharmacokinetics and antitumor activity of imexon. Invest new drugs 13:113–6
Bruno R, Hille D, Riva A et al (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187–96
Author information
Authors and Affiliations
Corresponding author
Additional information
Stacy Moulder, Navneet Dhillon have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Moulder, S., Dhillon, N., Ng, C. et al. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs 28, 634–640 (2010). https://doi.org/10.1007/s10637-009-9273-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-009-9273-1